Author:
Damaraju Vijaya L.,Kuzma Michelle,Cass Carol E.,Sawyer Michael B.
Funder
Alberta Innovates - Health Solutions
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference20 articles.
1. Mi Y, Lou L (2007) ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein. Br J Cancer 97(7):934–940
2. Damaraju VL, Kuzma M, Mowles D, Cass CE, Sawyer MB (2015) Interactions of multitargeted kinase inhibitors and nucleoside drugs: achilles heel of combination therapy? Mol Cancer Ther 14(1):236–245. doi: 10.1158/1535-7163.MCT-14-0337
3. Damaraju VL, Scriver T, Mowles D, Kuzma M, Ryan A, Cass CE, Sawyer MB (2014) Erlotinib, gefitinib and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-13-2293
4. Huang M, Wang Y, Cogut SB, Mitchell BS, Graves LM (2003) Inhibition of nucleoside transport by protein kinase inhibitors. J Pharmacol Exp Ther 304(2):753–760. doi: 10.1124/jpet.102.044214
5. Daniele G, Gallo M, Piccirillo MC, Giordano P, D’Alessio A, Del Giudice A, La Porta ML, Perrone F, Normanno N, De Luca A (2013) Pharmacokinetic evaluation of capecitabine in breast cancer. Expert Opin Drug Metab Toxicol 9(2):225–235. doi: 10.1517/17425255.2013.759939
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献